数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Timothy E. Sullivan Director 46 未披露 未持股 2017-03-31
Christy L. Shaffer Director 59 未披露 未持股 2017-03-31
Mark A. Velleca Chief Executive Officer, President and Director 53 133.48万 未持股 2017-03-31
Tyrell J. Rivers Director 44 未披露 未持股 2017-03-31
Christy L. Shaffer Director 59 未披露 未持股 2017-03-31
Glenn P. Muir Director 58 未披露 未持股 2017-03-31
Fredric N. Eshelman Director 68 未披露 未持股 2017-03-31
Fredric N. Eshelman Director 68 未披露 未持股 2017-03-31
Peter Kolchinsky Director 40 未披露 未持股 2017-03-31
Seth A. Rudnick Chairman of the Board of Directors 68 33.52万 未持股 2017-03-31

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Mark A. Velleca Chief Executive Officer, President and Director 53 133.48万 未持股 2017-03-31
Rajesh K. Malik Chief Medical Officer 58 68.87万 未持股 2017-03-31
Gregory J. Mossinghoff Chief Business Officer and Secretary 56 52.77万 未持股 2017-03-31
Jay Strum Chief Scientific Officer 53 未披露 未持股 2017-03-31
Jennifer K. Moses Vice President of Finance and Administration 42 未披露 未持股 2017-03-31

董事简历

中英对照 |  中文 |  英文
Timothy E. Sullivan

TimothyE.Sullivan自2016年5月以来一直担任我们的董事会成员。2014年1月,Sullivan先生加入AJU IB Investment,目前担任合伙人。此前,他曾担任RBS Citizens公司的生命科学投资银行主管(2011年12月至2014年1月),也曾担任Cornerstone Pharmaceuticals公司的执行Vice President兼公司开发主管(2010年3月至2011年12月)。他也曾担任Jefferies公司和Bear Stearns公司的投资银行家,专注于生命科学。Sullivan先生参与了超过200亿美元的资本和咨询的融资和并购交易。他之前的梦百合经验还包括在Cornerstone Pharmaceuticals从事3年的咨询、业务开发和运营,以及在Brigham&Women’s Hospital管理一个临床研究部门4年。Sullivan先生目前还担任MolecularTemplates,Inc.公司(一家私营生物制药公司)的董事。Sullivan先生在哥伦比亚商学院(Columbia Business School)获得工商管理硕士学位,并在哈佛学院(Harvard College)获得生物学学士学位。


Timothy E. Sullivan has served as a member of our board of directors since May 2016. In January 2014, Mr. Sullivan joined Aju IB Investment and currently serves as Partner. Previously, he was Head of Life Sciences Investment Banking at RBS Citizens from December 2011 to January 2014 and served as Executive Vice President and Head of Corporate Development at Cornerstone Pharmaceuticals from March 2010 to December 2011. He also was an investment banker focused on life sciences at Jefferies and Bear Stearns. Mr. Sullivan was involved in financing and M&A transactions in excess of $20 billion in capital and advisory. His previous healthcare experience also includes three years of advisory, business development and operations at Cornerstone Pharmaceuticals as well as four years managing a clinical research division within Brigham & Women's Hospital. Mr. Sullivan also currently serves as a director of Molecular Templates, Inc., a private biopharmaceutical company. Mr. Sullivan received his M.B.A. from Columbia Business School and his B.A. in Biology from Harvard College.
TimothyE.Sullivan自2016年5月以来一直担任我们的董事会成员。2014年1月,Sullivan先生加入AJU IB Investment,目前担任合伙人。此前,他曾担任RBS Citizens公司的生命科学投资银行主管(2011年12月至2014年1月),也曾担任Cornerstone Pharmaceuticals公司的执行Vice President兼公司开发主管(2010年3月至2011年12月)。他也曾担任Jefferies公司和Bear Stearns公司的投资银行家,专注于生命科学。Sullivan先生参与了超过200亿美元的资本和咨询的融资和并购交易。他之前的梦百合经验还包括在Cornerstone Pharmaceuticals从事3年的咨询、业务开发和运营,以及在Brigham&Women’s Hospital管理一个临床研究部门4年。Sullivan先生目前还担任MolecularTemplates,Inc.公司(一家私营生物制药公司)的董事。Sullivan先生在哥伦比亚商学院(Columbia Business School)获得工商管理硕士学位,并在哈佛学院(Harvard College)获得生物学学士学位。
Timothy E. Sullivan has served as a member of our board of directors since May 2016. In January 2014, Mr. Sullivan joined Aju IB Investment and currently serves as Partner. Previously, he was Head of Life Sciences Investment Banking at RBS Citizens from December 2011 to January 2014 and served as Executive Vice President and Head of Corporate Development at Cornerstone Pharmaceuticals from March 2010 to December 2011. He also was an investment banker focused on life sciences at Jefferies and Bear Stearns. Mr. Sullivan was involved in financing and M&A transactions in excess of $20 billion in capital and advisory. His previous healthcare experience also includes three years of advisory, business development and operations at Cornerstone Pharmaceuticals as well as four years managing a clinical research division within Brigham & Women's Hospital. Mr. Sullivan also currently serves as a director of Molecular Templates, Inc., a private biopharmaceutical company. Mr. Sullivan received his M.B.A. from Columbia Business School and his B.A. in Biology from Harvard College.
Christy L. Shaffer

Christy L. Shaffer,她曾一直担任我们的公司的董事,以及我们的董事会的主席(2012年1月以来)。2011年以来,她曾一直担任Hatteras Venture Partners公司(投资公司)的风险合伙人,以及Hatteras Discovery公司(投资生命科学行业早期企业)的董事总经理。1995年至2010年3月,她曾担任Inspire Pharmaceuticals公司(上市生物制药公司)的领导职务,并不断被提拔,始于担任公司的第一全职雇员,以及临床手术董事,最终于1999年被任命为公司的首席执行官和董事,于2005年被任命为总裁,还于2009年被任命为开发委员会的成员。任职Inspire公司之前,她曾担任Burroughs Wellcome Co。的临床研究科学家、国际项目负责人和肺部和重症护理医学副董事。她目前担任一些非盈利董事会的领导职务,包括担任the Morehead Planetarium and Science Center的咨询委员会的主席、the Cystic Fibrosis Foundation的监事会主席、CFF Therapeutic公司的董事会主席。她是受过训练的受体药理学家,并获得美国田纳西州大学(健康科学中心)(the University of Tennessee’s Health Science Center,位于田纳西州的孟菲斯)的药理学博士学位。她完成了The Chicago Medical School(芝加哥医学院)、the University of North Carolina at Chapel Hill(北卡罗莱纳大学教堂山分校)的博士后训练。美国证券交易委员会(sec)于2008年9月批准了一项非货币性结算调查,有关Inspire制药公司(Inspire Pharmaceuticals, Inc.)披露的有关临床试验的定期报告。委员会也批准了她作为Inspire公司的总裁兼首席执行官,以及董事会成员的一项结算,因此她同意停业和终止指令,以防违规证券交易法13a和法规12b-20、13a-13。停业和终止指令遵循欧盟委员会的裁决,由Inspire公司填写的以10-Q形式提交的3个季度报告,包括一个临床试验的误导信息披露,尤其是审判被形容为有效性试验早期发现的“验证”和“复制”。她既不承认也不否认任何发现,订单不包括任何违反任何法规和条例的任何发现,涉及任何故意的不当行为或欺诈、其它货币支付或制裁、其它影响她的未来就业状况,也没有否认她在上市公司董事会上的任职的任何能力。


Christy L. Shaffer,Dr. Shaffer has served as a director of our company since January 2012 and as the chairman of our board of directors from January 2012 to February 2018. Since 2011 Dr. Shaffer has served as a Venture Partner with Hatteras Venture Partners, an investment firm, and as Managing Director of Hatteras Discovery, which invests in early-stage companies in the life sciences industry sector. From 1995 to March 2010 Dr. Shaffer served in increasing leadership positions at Inspire Pharmaceuticals, a publicly held biopharmaceutical company, beginning as the company’s first full-time employee and Director of Clinical Operations and eventually being appointed as Chief Executive Officer and a director of the company in 1999 as its President in 2005 and a member of its Development Committee in 2009. Prior to Inspire, she was a clinical research scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co. Dr. Shaffer currently serves as a board member of the Chordoma Foundation and has served in leadership roles on several non-profit boards, including as chair of the Morehead Planetarium and Science Center’s advisory board, on the Board of Trustees for the Cystic Fibrosis Foundation, and as chair of the board of CFF Therapeutic, Inc. Dr. Shaffer currently serves on the board of G1 Therapeutics, Inc., a publicly traded biopharmaceutical company. Dr. Shaffer is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee’s Health Science Center in Memphis, Tennessee. She completed post-doctoral training at The Chicago Medical School as well as the University of North Carolina at Chapel Hill. In September 2008 the Securities and Exchange Commission approved a non-monetary settlement of its investigation relating to Inspire Pharmaceuticals’ disclosures in its periodic reports relating to a clinical trial. The Commission also approved a settlement with Dr. Shaffer, as Inspire’s President and Chief Executive Officer and a member of its board of directors, under which she consented to a cease and desist order against future violations of Section 13a of the Exchange Act and Rules 12b-20 and 13a-13 thereunder. The cease and desist order followed a finding by the Commission that three Quarterly Reports on Form 10-Q filed by Inspire included misleading disclosure about a clinical trial, specifically that the trial was described as “confirmatory” and “replicating” the efficacy found in an earlier trial. Dr. Shaffer did not admit or deny any findings in the order, and the order did not include any finding of any violation of any statute or regulation that involved any intentional wrongdoing or fraud, any monetary payments or other sanctions or otherwise affect Dr. Shaffer’s future employment status, nor did it prohibit Dr. Shaffer from serving in any capacity on public company boards of directors.
Christy L. Shaffer,她曾一直担任我们的公司的董事,以及我们的董事会的主席(2012年1月以来)。2011年以来,她曾一直担任Hatteras Venture Partners公司(投资公司)的风险合伙人,以及Hatteras Discovery公司(投资生命科学行业早期企业)的董事总经理。1995年至2010年3月,她曾担任Inspire Pharmaceuticals公司(上市生物制药公司)的领导职务,并不断被提拔,始于担任公司的第一全职雇员,以及临床手术董事,最终于1999年被任命为公司的首席执行官和董事,于2005年被任命为总裁,还于2009年被任命为开发委员会的成员。任职Inspire公司之前,她曾担任Burroughs Wellcome Co。的临床研究科学家、国际项目负责人和肺部和重症护理医学副董事。她目前担任一些非盈利董事会的领导职务,包括担任the Morehead Planetarium and Science Center的咨询委员会的主席、the Cystic Fibrosis Foundation的监事会主席、CFF Therapeutic公司的董事会主席。她是受过训练的受体药理学家,并获得美国田纳西州大学(健康科学中心)(the University of Tennessee’s Health Science Center,位于田纳西州的孟菲斯)的药理学博士学位。她完成了The Chicago Medical School(芝加哥医学院)、the University of North Carolina at Chapel Hill(北卡罗莱纳大学教堂山分校)的博士后训练。美国证券交易委员会(sec)于2008年9月批准了一项非货币性结算调查,有关Inspire制药公司(Inspire Pharmaceuticals, Inc.)披露的有关临床试验的定期报告。委员会也批准了她作为Inspire公司的总裁兼首席执行官,以及董事会成员的一项结算,因此她同意停业和终止指令,以防违规证券交易法13a和法规12b-20、13a-13。停业和终止指令遵循欧盟委员会的裁决,由Inspire公司填写的以10-Q形式提交的3个季度报告,包括一个临床试验的误导信息披露,尤其是审判被形容为有效性试验早期发现的“验证”和“复制”。她既不承认也不否认任何发现,订单不包括任何违反任何法规和条例的任何发现,涉及任何故意的不当行为或欺诈、其它货币支付或制裁、其它影响她的未来就业状况,也没有否认她在上市公司董事会上的任职的任何能力。
Christy L. Shaffer,Dr. Shaffer has served as a director of our company since January 2012 and as the chairman of our board of directors from January 2012 to February 2018. Since 2011 Dr. Shaffer has served as a Venture Partner with Hatteras Venture Partners, an investment firm, and as Managing Director of Hatteras Discovery, which invests in early-stage companies in the life sciences industry sector. From 1995 to March 2010 Dr. Shaffer served in increasing leadership positions at Inspire Pharmaceuticals, a publicly held biopharmaceutical company, beginning as the company’s first full-time employee and Director of Clinical Operations and eventually being appointed as Chief Executive Officer and a director of the company in 1999 as its President in 2005 and a member of its Development Committee in 2009. Prior to Inspire, she was a clinical research scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co. Dr. Shaffer currently serves as a board member of the Chordoma Foundation and has served in leadership roles on several non-profit boards, including as chair of the Morehead Planetarium and Science Center’s advisory board, on the Board of Trustees for the Cystic Fibrosis Foundation, and as chair of the board of CFF Therapeutic, Inc. Dr. Shaffer currently serves on the board of G1 Therapeutics, Inc., a publicly traded biopharmaceutical company. Dr. Shaffer is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee’s Health Science Center in Memphis, Tennessee. She completed post-doctoral training at The Chicago Medical School as well as the University of North Carolina at Chapel Hill. In September 2008 the Securities and Exchange Commission approved a non-monetary settlement of its investigation relating to Inspire Pharmaceuticals’ disclosures in its periodic reports relating to a clinical trial. The Commission also approved a settlement with Dr. Shaffer, as Inspire’s President and Chief Executive Officer and a member of its board of directors, under which she consented to a cease and desist order against future violations of Section 13a of the Exchange Act and Rules 12b-20 and 13a-13 thereunder. The cease and desist order followed a finding by the Commission that three Quarterly Reports on Form 10-Q filed by Inspire included misleading disclosure about a clinical trial, specifically that the trial was described as “confirmatory” and “replicating” the efficacy found in an earlier trial. Dr. Shaffer did not admit or deny any findings in the order, and the order did not include any finding of any violation of any statute or regulation that involved any intentional wrongdoing or fraud, any monetary payments or other sanctions or otherwise affect Dr. Shaffer’s future employment status, nor did it prohibit Dr. Shaffer from serving in any capacity on public company boards of directors.
Mark A. Velleca

MarkA.Velleca,医学博士,博士,自2014年5月起担任公司首席执行官,总裁兼董事会成员。在加入我们之前,Velleca博士从1999年到2010年是CGI Pharmaceuticals,Inc.或CGI(一家生物制药公司)的联合创始人和高级副总裁,在那里他从公司成立到多个候选药物的临床试验管理公司。CGI于2010年被生物技术公司吉利德科学公司(Gilead)收购后,Velleca博士从2010年到2012年4月担任Gilead的高级顾问,他在该公司帮助建立肿瘤管道。Velleca从2010年到2012年担任BioMarker Strategies(一家私营肿瘤诊断公司)董事会成员,从2007年到2012年担任BioRelix Inc.(一家生物制药公司)科学顾问委员会成员,从2007年到2010年担任Intellikine,Inc.(一家生物制药公司)科学顾问委员会成员。Velleca博士最近于2012年4月至2014年4月担任白血病和淋巴瘤协会执行Vice President。Velleca博士还担任耶鲁大学纽黑文医院(Yale New Haven Hospital)和耶鲁大学医学院(Yale University School of Medicine)的主治医师。Velleca博士在耶鲁大学(Yale University)获得学士学位,在圣路易斯(St.Louis)的华盛顿大学(Washington University)获得医学博士和博士学位。


Mark A. Velleca, M.D., Ph.D., has served as our Chief Executive Officer, President and a member of our board of directors since May 2014. Prior to joining us, Dr. Velleca was a co-founder and served as Senior Vice President of CGI Pharmaceuticals, Inc., or CGI, a biopharmaceutical company, from 1999 to 2010 where he managed the company from its inception through clinical trials of multiple drug candidates. After CGI was acquired by Gilead Sciences, Inc., or Gilead, a biotechnology company, in 2010 Dr. Velleca served as a Senior Advisor to Gilead from 2010 to April 2012 where he worked to help build its oncology pipeline. Dr. Velleca has served on the board of directors of BioMarker Strategies, a private oncology diagnostics company, from 2010 to 2012 and on the scientific advisory boards of BioRelix Inc., a biopharmaceutical company, from 2007 to 2012 and Intellikine, Inc., a biopharmaceutical company, from 2007 to 2010. Dr. Velleca most recently served as Executive Vice President at The Leukemia & Lymphoma Society from April 2012 to April 2014. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Dr. Velleca received his B.S. from Yale University, and his M.D. and Ph.D. from Washington University in St. Louis.
MarkA.Velleca,医学博士,博士,自2014年5月起担任公司首席执行官,总裁兼董事会成员。在加入我们之前,Velleca博士从1999年到2010年是CGI Pharmaceuticals,Inc.或CGI(一家生物制药公司)的联合创始人和高级副总裁,在那里他从公司成立到多个候选药物的临床试验管理公司。CGI于2010年被生物技术公司吉利德科学公司(Gilead)收购后,Velleca博士从2010年到2012年4月担任Gilead的高级顾问,他在该公司帮助建立肿瘤管道。Velleca从2010年到2012年担任BioMarker Strategies(一家私营肿瘤诊断公司)董事会成员,从2007年到2012年担任BioRelix Inc.(一家生物制药公司)科学顾问委员会成员,从2007年到2010年担任Intellikine,Inc.(一家生物制药公司)科学顾问委员会成员。Velleca博士最近于2012年4月至2014年4月担任白血病和淋巴瘤协会执行Vice President。Velleca博士还担任耶鲁大学纽黑文医院(Yale New Haven Hospital)和耶鲁大学医学院(Yale University School of Medicine)的主治医师。Velleca博士在耶鲁大学(Yale University)获得学士学位,在圣路易斯(St.Louis)的华盛顿大学(Washington University)获得医学博士和博士学位。
Mark A. Velleca, M.D., Ph.D., has served as our Chief Executive Officer, President and a member of our board of directors since May 2014. Prior to joining us, Dr. Velleca was a co-founder and served as Senior Vice President of CGI Pharmaceuticals, Inc., or CGI, a biopharmaceutical company, from 1999 to 2010 where he managed the company from its inception through clinical trials of multiple drug candidates. After CGI was acquired by Gilead Sciences, Inc., or Gilead, a biotechnology company, in 2010 Dr. Velleca served as a Senior Advisor to Gilead from 2010 to April 2012 where he worked to help build its oncology pipeline. Dr. Velleca has served on the board of directors of BioMarker Strategies, a private oncology diagnostics company, from 2010 to 2012 and on the scientific advisory boards of BioRelix Inc., a biopharmaceutical company, from 2007 to 2012 and Intellikine, Inc., a biopharmaceutical company, from 2007 to 2010. Dr. Velleca most recently served as Executive Vice President at The Leukemia & Lymphoma Society from April 2012 to April 2014. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Dr. Velleca received his B.S. from Yale University, and his M.D. and Ph.D. from Washington University in St. Louis.
Tyrell J. Rivers

TyrellJ.Rivers博士自2017年3月以来一直担任我们的董事会成员。Rivers博士是阿斯利康公司(AstraZeneca&8217;)企业发展集团的执行董事,负责战略股权投资、并购和撤资,自2014年5月起担任该职位。加入AstraZeneca公司之前,他曾任职MedImmune Ventures公司(从2009年10月到2014年5月),在那里他专门从事生物技术投资,也曾任职Merck&Co.,从2001年到2007年,他领导多个商业疫苗专营权的技术支持,随后指导全球商业计划,以获得研究与开发的关键技术。Rivers博士在麻省理工学院(Massachusetts Institute of Technology)获得化学工程学士学位,在德克萨斯大学奥斯汀分校(University of Texas at Austin)获得化学工程博士学位,在纽约大学斯特恩商学院(Stern School of Business)获得工商管理硕士学位。Rivers博士还担任私营临床阶段生物技术公司Armaron Bio Ltd.和私营生物技术公司Corvidia Therapeutics的董事会成员。


Tyrell J. Rivers, Ph.D., has served as a member of our board of directors since March 2017. Dr. Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments and has served in this role since May 2014. Prior to joining AstraZeneca, Dr. Rivers was at MedImmune Ventures from October 2009 until May 2014 where he specialized in biotechnology investing, and at Merck & Co., Inc. from 2001 through 2007 where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and his M.B.A. from the New York University Stern School of Business. Dr. Rivers also serves on the board of directors for Armaron Bio Ltd., a private clinical stage biotechnology company, and Corvidia Therapeutics, a private biotechnology company.
TyrellJ.Rivers博士自2017年3月以来一直担任我们的董事会成员。Rivers博士是阿斯利康公司(AstraZeneca&8217;)企业发展集团的执行董事,负责战略股权投资、并购和撤资,自2014年5月起担任该职位。加入AstraZeneca公司之前,他曾任职MedImmune Ventures公司(从2009年10月到2014年5月),在那里他专门从事生物技术投资,也曾任职Merck&Co.,从2001年到2007年,他领导多个商业疫苗专营权的技术支持,随后指导全球商业计划,以获得研究与开发的关键技术。Rivers博士在麻省理工学院(Massachusetts Institute of Technology)获得化学工程学士学位,在德克萨斯大学奥斯汀分校(University of Texas at Austin)获得化学工程博士学位,在纽约大学斯特恩商学院(Stern School of Business)获得工商管理硕士学位。Rivers博士还担任私营临床阶段生物技术公司Armaron Bio Ltd.和私营生物技术公司Corvidia Therapeutics的董事会成员。
Tyrell J. Rivers, Ph.D., has served as a member of our board of directors since March 2017. Dr. Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments and has served in this role since May 2014. Prior to joining AstraZeneca, Dr. Rivers was at MedImmune Ventures from October 2009 until May 2014 where he specialized in biotechnology investing, and at Merck & Co., Inc. from 2001 through 2007 where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and his M.B.A. from the New York University Stern School of Business. Dr. Rivers also serves on the board of directors for Armaron Bio Ltd., a private clinical stage biotechnology company, and Corvidia Therapeutics, a private biotechnology company.
Christy L. Shaffer
暂无中文简介

Christy L. Shaffer, Ph.D., has served as a member of our board of directors since August 2012 and from 2012 until 2014 Dr. Shaffer served as the Executive Chairperson of our board of directors. Dr. Shaffer was the Chief Executive Officer and President of Inspire Pharmaceuticals, Inc., or Inspire, until her retirement in February 2010. Inspire is a biopharmaceutical company that was acquired by Merck & Co., Inc. in 2011. Following her retirement, Dr. Shaffer served as a consultant to Inspire until February 2012. From August 2011 to August 2015 Dr. Shaffer served as a Venture Partner of Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals and related opportunities in human medicine, and as a Managing Director of Hatteras Discovery, which is a part of Hatteras Venture Partners. Since August 2015 Dr. Shaffer has served as a General Partner of Hatteras Venture Partners. Dr. Shaffer has served as a member of the board of Clearside Biomedical Inc., a publicly traded biopharmaceutical company, since January 2012. Dr. Shaffer also serves as a member of the boards of directors of privately held life sciences companies, including Artizan Biosciences, Inc., Spyryx Biosciences, Inc., Trefoil Therapeutics, Inc., KinoDyn Inc., for which she serves as Chairperson of the board of directors, and GrayBug, Inc., for which she serves as Chairperson of the board of directors. In September 2008 the Securities and Exchange Commission approved a non-monetary settlement of its investigation relating to Inspire’s disclosures in its periodic reports relating to a clinical trial. The Securities and Exchange Commission also approved a settlement with Dr. Shaffer, as Inspire’s President and Chief Executive Officer and a member of its board of directors, under which she consented to a cease and desist order against future violations of Section 13a of the Exchange Act and Rules 12b-20 and 13a-13 thereunder. The cease and desist order followed a finding by the Securities and Exchange Commission that three Quarterly Reports on Form 10-Q filed by Inspire included misleading disclosure about a clinical trial, specifically that the trial was described as “confirmatory” and “replicating” the efficacy found in an earlier trial. Dr. Shaffer did not admit or deny any findings in the order, and the order did not include any finding of any violation of any statute or regulation that involved any intentional wrongdoing or fraud, any monetary payments or other sanctions or otherwise affect Dr. Shaffer’s future employment status, nor did it prohibit Dr. Shaffer from serving in any capacity on public company boards of directors. Dr. Shaffer received her Ph.D. in Pharmacology from the University of Tennessee Health Science Center.
暂无中文简介
Christy L. Shaffer, Ph.D., has served as a member of our board of directors since August 2012 and from 2012 until 2014 Dr. Shaffer served as the Executive Chairperson of our board of directors. Dr. Shaffer was the Chief Executive Officer and President of Inspire Pharmaceuticals, Inc., or Inspire, until her retirement in February 2010. Inspire is a biopharmaceutical company that was acquired by Merck & Co., Inc. in 2011. Following her retirement, Dr. Shaffer served as a consultant to Inspire until February 2012. From August 2011 to August 2015 Dr. Shaffer served as a Venture Partner of Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals and related opportunities in human medicine, and as a Managing Director of Hatteras Discovery, which is a part of Hatteras Venture Partners. Since August 2015 Dr. Shaffer has served as a General Partner of Hatteras Venture Partners. Dr. Shaffer has served as a member of the board of Clearside Biomedical Inc., a publicly traded biopharmaceutical company, since January 2012. Dr. Shaffer also serves as a member of the boards of directors of privately held life sciences companies, including Artizan Biosciences, Inc., Spyryx Biosciences, Inc., Trefoil Therapeutics, Inc., KinoDyn Inc., for which she serves as Chairperson of the board of directors, and GrayBug, Inc., for which she serves as Chairperson of the board of directors. In September 2008 the Securities and Exchange Commission approved a non-monetary settlement of its investigation relating to Inspire’s disclosures in its periodic reports relating to a clinical trial. The Securities and Exchange Commission also approved a settlement with Dr. Shaffer, as Inspire’s President and Chief Executive Officer and a member of its board of directors, under which she consented to a cease and desist order against future violations of Section 13a of the Exchange Act and Rules 12b-20 and 13a-13 thereunder. The cease and desist order followed a finding by the Securities and Exchange Commission that three Quarterly Reports on Form 10-Q filed by Inspire included misleading disclosure about a clinical trial, specifically that the trial was described as “confirmatory” and “replicating” the efficacy found in an earlier trial. Dr. Shaffer did not admit or deny any findings in the order, and the order did not include any finding of any violation of any statute or regulation that involved any intentional wrongdoing or fraud, any monetary payments or other sanctions or otherwise affect Dr. Shaffer’s future employment status, nor did it prohibit Dr. Shaffer from serving in any capacity on public company boards of directors. Dr. Shaffer received her Ph.D. in Pharmacology from the University of Tennessee Health Science Center.
Glenn P. Muir

Glenn P. Muir, 2015年10月以来,他一直担任Repligen的董事。Muir于2014年5月从Hologic退休,在那里他帮助公司从一家风险投资支持的单一产品公司发展成为一家拥有5000多名员工和25亿美元收入的上市多元化组织。他于1988年加入Hologic, 1992年以来担任首席财务官,2000年以来担任执行副总裁。加入Hologic之前,他曾任职于私人公司Metallon Engineered Materials Co.(1986-1988),担任财务副总裁。此前,从1981年到1984年,他是Arthur Andersen & Co.的高级审计师。Muir先生还担任两家上市公司的董事会成员;医疗技术公司Neuronetics, Inc.和生命科学公司G1 Therapeutics, Inc.。此前,Muir先生于2014年7月至2017年12月担任ReWalk Robotics Ltd.的董事会成员。他是一名注册会计师,拥有the University of Massachusetts, Amherst的工商管理学士学位。他还获得了Bentley大学的硕士学位和哈佛大学的工商管理硕士学位。


Glenn P. Muir has served as a director of Repligen since October 2015.Mr. Muir retired in May 2014 from Hologic, where he helped steer the company's evolution from a venture-backed single product company to a publicly traded diversified organization with over 5000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984 he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies; medical technology company Neuronetics, Inc. and life science company G1 Therapeutics, Inc. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University.
Glenn P. Muir, 2015年10月以来,他一直担任Repligen的董事。Muir于2014年5月从Hologic退休,在那里他帮助公司从一家风险投资支持的单一产品公司发展成为一家拥有5000多名员工和25亿美元收入的上市多元化组织。他于1988年加入Hologic, 1992年以来担任首席财务官,2000年以来担任执行副总裁。加入Hologic之前,他曾任职于私人公司Metallon Engineered Materials Co.(1986-1988),担任财务副总裁。此前,从1981年到1984年,他是Arthur Andersen & Co.的高级审计师。Muir先生还担任两家上市公司的董事会成员;医疗技术公司Neuronetics, Inc.和生命科学公司G1 Therapeutics, Inc.。此前,Muir先生于2014年7月至2017年12月担任ReWalk Robotics Ltd.的董事会成员。他是一名注册会计师,拥有the University of Massachusetts, Amherst的工商管理学士学位。他还获得了Bentley大学的硕士学位和哈佛大学的工商管理硕士学位。
Glenn P. Muir has served as a director of Repligen since October 2015.Mr. Muir retired in May 2014 from Hologic, where he helped steer the company's evolution from a venture-backed single product company to a publicly traded diversified organization with over 5000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984 he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies; medical technology company Neuronetics, Inc. and life science company G1 Therapeutics, Inc. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University.
Fredric N. Eshelman

Fredric N. Eshelman,2009年7月起,担任本公司的执行董事长。1990年7月至2009年7月,他担任本公司的首席执行官;1993年7月至2009年7月,担任副董事长。他是本公司前身的创始人,并担任首席执行官,直到1989年将其出售给本公司。回到本公司之前,1989-1990,他是Glaxo Holdings plc子公司Glaxo Inc.的开发高级副总裁、董事。他现为Furiex Pharmaceuticals, Inc.的董事长、顾问。


Fredric N. Eshelman,Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. PPD and founding chairman of Furiex Pharmaceuticals, Inc. In 2014 Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From 2009 to 2014 Dr. Eshelman served as chairman of the Board of Furiex. From 2009 to 2011 he served as executive chairman of PPD. He also served as chief executive officer of PPD from 1990 to 2009 and as vice chairman of its Board of Directors from 1993 to 2009. Dr. Eshelman currently serves on the board of directors of Valeant Pharmaceuticals International, Inc. and G1 Therapeutics, Inc. Dr. Eshelman received a bachelor’s degree in pharmacy from UNC Chapel Hill and a doctorate in pharmacy from the University of Cincinnati, and he completed an OPM program at Harvard University.
Fredric N. Eshelman,2009年7月起,担任本公司的执行董事长。1990年7月至2009年7月,他担任本公司的首席执行官;1993年7月至2009年7月,担任副董事长。他是本公司前身的创始人,并担任首席执行官,直到1989年将其出售给本公司。回到本公司之前,1989-1990,他是Glaxo Holdings plc子公司Glaxo Inc.的开发高级副总裁、董事。他现为Furiex Pharmaceuticals, Inc.的董事长、顾问。
Fredric N. Eshelman,Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. PPD and founding chairman of Furiex Pharmaceuticals, Inc. In 2014 Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From 2009 to 2014 Dr. Eshelman served as chairman of the Board of Furiex. From 2009 to 2011 he served as executive chairman of PPD. He also served as chief executive officer of PPD from 1990 to 2009 and as vice chairman of its Board of Directors from 1993 to 2009. Dr. Eshelman currently serves on the board of directors of Valeant Pharmaceuticals International, Inc. and G1 Therapeutics, Inc. Dr. Eshelman received a bachelor’s degree in pharmacy from UNC Chapel Hill and a doctorate in pharmacy from the University of Cincinnati, and he completed an OPM program at Harvard University.
Fredric N. Eshelman

Fredric N. Eshelman,他是一名药学博士。自本公司于2009年成立以来,他在本公司担任董事会主席。自2009年7月至2011年12月,他在Pharmaceutical Product Development公司 ("PPD")担任董事会执行主席。该公司于2011年12月进行资本清算。自1990年7月至2009年7月,他在PPD公司担任首席执行官。自1993年7月至2009年7月,他担任董事会副总裁。他建立了PPD公司的前身公司并担任了首席执行官,直至1989年该公司被PPD公司收购。自1989年至1990年,他在Glaxo公司担任开发方面的高级副总裁以及董事。Glaxo公司是Glaxo Holdings plc公司的子公司。他在美国北卡罗来纳州生物技术中心担任董事。


Fredric N. Eshelman,was appointed the Executive Chairman of Aravive, Inc. on January 3, 2022 and has served as the non-executive Chairman of the Board of Directors from April 8, 2020 until his appointment as Executive Chairman of Aravive, Inc. Dr. Eshelman is the Founder of Eshelman Ventures, LLC, an investment company primarily interested in healthcare companies. Previously, he founded and served as Chairman and Chief Executive Officer of Pharmaceutical Product Development, Inc. (PPDI) prior to the sale of the company to private equity interests. After PPD, he served as founding chairman and was the largest shareholder of Furiex Pharmaceuticals, Inc. (FURX), a company which in-licensed and rapidly developed new medicines. Furiex was sold to Forest Laboratories Inc. (which was later acquired by Actavis) in 2014. His career has also included positions as SVP development and board member of the former Glaxo, Inc., as well as management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman is also a member of the Board of Directors of, Amplitude Healthcare Acquisition Corp. and Eyenovia Inc. He is currently chairman of several biotech companies and previously was chairman of The Medicines Company (MDCO) and was on the board of Bausch Health (BHC) G1 Therapeutics, Inc. Dr. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system (chair of audit committee), as well as the North Carolina Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at University of North Carolina at Charlotte (UNC-CH). The school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.He has received many awards including the Davie and Distinguished Service Awards from UNC, outstanding alumnus from both the UNC and University of Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the North Carolina Biotech Hall of Fame. Dr. Eshelman received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital, and received a BS Pharm from UNC-CH. He completed the OPM program at Harvard Business School. Dr. Eshelman also received an honorary doctor of science from UNC-CH.
Fredric N. Eshelman,他是一名药学博士。自本公司于2009年成立以来,他在本公司担任董事会主席。自2009年7月至2011年12月,他在Pharmaceutical Product Development公司 ("PPD")担任董事会执行主席。该公司于2011年12月进行资本清算。自1990年7月至2009年7月,他在PPD公司担任首席执行官。自1993年7月至2009年7月,他担任董事会副总裁。他建立了PPD公司的前身公司并担任了首席执行官,直至1989年该公司被PPD公司收购。自1989年至1990年,他在Glaxo公司担任开发方面的高级副总裁以及董事。Glaxo公司是Glaxo Holdings plc公司的子公司。他在美国北卡罗来纳州生物技术中心担任董事。
Fredric N. Eshelman,was appointed the Executive Chairman of Aravive, Inc. on January 3, 2022 and has served as the non-executive Chairman of the Board of Directors from April 8, 2020 until his appointment as Executive Chairman of Aravive, Inc. Dr. Eshelman is the Founder of Eshelman Ventures, LLC, an investment company primarily interested in healthcare companies. Previously, he founded and served as Chairman and Chief Executive Officer of Pharmaceutical Product Development, Inc. (PPDI) prior to the sale of the company to private equity interests. After PPD, he served as founding chairman and was the largest shareholder of Furiex Pharmaceuticals, Inc. (FURX), a company which in-licensed and rapidly developed new medicines. Furiex was sold to Forest Laboratories Inc. (which was later acquired by Actavis) in 2014. His career has also included positions as SVP development and board member of the former Glaxo, Inc., as well as management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman is also a member of the Board of Directors of, Amplitude Healthcare Acquisition Corp. and Eyenovia Inc. He is currently chairman of several biotech companies and previously was chairman of The Medicines Company (MDCO) and was on the board of Bausch Health (BHC) G1 Therapeutics, Inc. Dr. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system (chair of audit committee), as well as the North Carolina Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at University of North Carolina at Charlotte (UNC-CH). The school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.He has received many awards including the Davie and Distinguished Service Awards from UNC, outstanding alumnus from both the UNC and University of Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the North Carolina Biotech Hall of Fame. Dr. Eshelman received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital, and received a BS Pharm from UNC-CH. He completed the OPM program at Harvard Business School. Dr. Eshelman also received an honorary doctor of science from UNC-CH.
Peter Kolchinsky

Peter Kolchinsky,他是一名博士,自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月,他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃,投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍,并在American Fertility Association公司担任董事。目前,他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院(National Academies of Sciences)的全球科技委员会任职。他在哈佛大学(Harvard University)获得病毒学博士学位,并在美国康乃尔大学(Cornell University)获得学士学位。


Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-defined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University.
Peter Kolchinsky,他是一名博士,自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月,他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃,投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍,并在American Fertility Association公司担任董事。目前,他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院(National Academies of Sciences)的全球科技委员会任职。他在哈佛大学(Harvard University)获得病毒学博士学位,并在美国康乃尔大学(Cornell University)获得学士学位。
Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-defined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University.
Seth A. Rudnick

Seth A. Rudnick, 他是Canaan Partners公司(全球风险投资公司)的退休合伙人,在那里他领导公司在医疗公司的投资(从1998年到2013年)。此前,他曾担任CytoTherapeutics公司(公司专注于干细胞疗法的发展和商业化)的董事会主席兼首席执行官,也曾担任R.W. Johnson Pharmaceutical Research Institute(在那里领导所有的研究和开发活动,并管理学院在加利福尼亚圣迭戈的生物技术中心)的负责生物技术研究与开发的高级副总裁。他也曾任职Pozen, Liquidia公司、Envisia公司、G1 Therapeutics公司、Vaxinnate公司、Meryx公司的董事会。他是The Emory Drug Development Institute、DRIVE、G1 Therapeutics公司的科学顾问委员会的主席。


Seth A. Rudnick, M.D. has been a director of the Company and Chairperson of the Nominating/Corporate Governance Committee since February 2016. Previously, he was a director of Pozen from 2011 to February 2016. Dr. Rudnick was a venture partner and previously general partner at Canaan Partners, a venture capital firm, from 1998 to December 2014. Formerly, Dr. Rudnick was the Chief Executive Officer and Chairperson of CytoTherapeutics Inc., a company developing stem cell-based therapies, from 1991 to 1998. He helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson, focusing on cancer and chronic illnesses from 1986 to 1991. He currently serves on the boards of directors of the following privately held biotechnology companies: Liquidia, for which he serves as Chairperson, and G1 Therapeutics, for which he serves as Chairperson. Dr. Rudnick also served on the board of directors of Square 1 Financial, Inc., a public financial services company, from 2012 to October 2015. Currently he is a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill.
Seth A. Rudnick, 他是Canaan Partners公司(全球风险投资公司)的退休合伙人,在那里他领导公司在医疗公司的投资(从1998年到2013年)。此前,他曾担任CytoTherapeutics公司(公司专注于干细胞疗法的发展和商业化)的董事会主席兼首席执行官,也曾担任R.W. Johnson Pharmaceutical Research Institute(在那里领导所有的研究和开发活动,并管理学院在加利福尼亚圣迭戈的生物技术中心)的负责生物技术研究与开发的高级副总裁。他也曾任职Pozen, Liquidia公司、Envisia公司、G1 Therapeutics公司、Vaxinnate公司、Meryx公司的董事会。他是The Emory Drug Development Institute、DRIVE、G1 Therapeutics公司的科学顾问委员会的主席。
Seth A. Rudnick, M.D. has been a director of the Company and Chairperson of the Nominating/Corporate Governance Committee since February 2016. Previously, he was a director of Pozen from 2011 to February 2016. Dr. Rudnick was a venture partner and previously general partner at Canaan Partners, a venture capital firm, from 1998 to December 2014. Formerly, Dr. Rudnick was the Chief Executive Officer and Chairperson of CytoTherapeutics Inc., a company developing stem cell-based therapies, from 1991 to 1998. He helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson, focusing on cancer and chronic illnesses from 1986 to 1991. He currently serves on the boards of directors of the following privately held biotechnology companies: Liquidia, for which he serves as Chairperson, and G1 Therapeutics, for which he serves as Chairperson. Dr. Rudnick also served on the board of directors of Square 1 Financial, Inc., a public financial services company, from 2012 to October 2015. Currently he is a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill.

高管简历

中英对照 |  中文 |  英文
Mark A. Velleca

MarkA.Velleca,医学博士,博士,自2014年5月起担任公司首席执行官,总裁兼董事会成员。在加入我们之前,Velleca博士从1999年到2010年是CGI Pharmaceuticals,Inc.或CGI(一家生物制药公司)的联合创始人和高级副总裁,在那里他从公司成立到多个候选药物的临床试验管理公司。CGI于2010年被生物技术公司吉利德科学公司(Gilead)收购后,Velleca博士从2010年到2012年4月担任Gilead的高级顾问,他在该公司帮助建立肿瘤管道。Velleca从2010年到2012年担任BioMarker Strategies(一家私营肿瘤诊断公司)董事会成员,从2007年到2012年担任BioRelix Inc.(一家生物制药公司)科学顾问委员会成员,从2007年到2010年担任Intellikine,Inc.(一家生物制药公司)科学顾问委员会成员。Velleca博士最近于2012年4月至2014年4月担任白血病和淋巴瘤协会执行Vice President。Velleca博士还担任耶鲁大学纽黑文医院(Yale New Haven Hospital)和耶鲁大学医学院(Yale University School of Medicine)的主治医师。Velleca博士在耶鲁大学(Yale University)获得学士学位,在圣路易斯(St.Louis)的华盛顿大学(Washington University)获得医学博士和博士学位。


Mark A. Velleca, M.D., Ph.D., has served as our Chief Executive Officer, President and a member of our board of directors since May 2014. Prior to joining us, Dr. Velleca was a co-founder and served as Senior Vice President of CGI Pharmaceuticals, Inc., or CGI, a biopharmaceutical company, from 1999 to 2010 where he managed the company from its inception through clinical trials of multiple drug candidates. After CGI was acquired by Gilead Sciences, Inc., or Gilead, a biotechnology company, in 2010 Dr. Velleca served as a Senior Advisor to Gilead from 2010 to April 2012 where he worked to help build its oncology pipeline. Dr. Velleca has served on the board of directors of BioMarker Strategies, a private oncology diagnostics company, from 2010 to 2012 and on the scientific advisory boards of BioRelix Inc., a biopharmaceutical company, from 2007 to 2012 and Intellikine, Inc., a biopharmaceutical company, from 2007 to 2010. Dr. Velleca most recently served as Executive Vice President at The Leukemia & Lymphoma Society from April 2012 to April 2014. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Dr. Velleca received his B.S. from Yale University, and his M.D. and Ph.D. from Washington University in St. Louis.
MarkA.Velleca,医学博士,博士,自2014年5月起担任公司首席执行官,总裁兼董事会成员。在加入我们之前,Velleca博士从1999年到2010年是CGI Pharmaceuticals,Inc.或CGI(一家生物制药公司)的联合创始人和高级副总裁,在那里他从公司成立到多个候选药物的临床试验管理公司。CGI于2010年被生物技术公司吉利德科学公司(Gilead)收购后,Velleca博士从2010年到2012年4月担任Gilead的高级顾问,他在该公司帮助建立肿瘤管道。Velleca从2010年到2012年担任BioMarker Strategies(一家私营肿瘤诊断公司)董事会成员,从2007年到2012年担任BioRelix Inc.(一家生物制药公司)科学顾问委员会成员,从2007年到2010年担任Intellikine,Inc.(一家生物制药公司)科学顾问委员会成员。Velleca博士最近于2012年4月至2014年4月担任白血病和淋巴瘤协会执行Vice President。Velleca博士还担任耶鲁大学纽黑文医院(Yale New Haven Hospital)和耶鲁大学医学院(Yale University School of Medicine)的主治医师。Velleca博士在耶鲁大学(Yale University)获得学士学位,在圣路易斯(St.Louis)的华盛顿大学(Washington University)获得医学博士和博士学位。
Mark A. Velleca, M.D., Ph.D., has served as our Chief Executive Officer, President and a member of our board of directors since May 2014. Prior to joining us, Dr. Velleca was a co-founder and served as Senior Vice President of CGI Pharmaceuticals, Inc., or CGI, a biopharmaceutical company, from 1999 to 2010 where he managed the company from its inception through clinical trials of multiple drug candidates. After CGI was acquired by Gilead Sciences, Inc., or Gilead, a biotechnology company, in 2010 Dr. Velleca served as a Senior Advisor to Gilead from 2010 to April 2012 where he worked to help build its oncology pipeline. Dr. Velleca has served on the board of directors of BioMarker Strategies, a private oncology diagnostics company, from 2010 to 2012 and on the scientific advisory boards of BioRelix Inc., a biopharmaceutical company, from 2007 to 2012 and Intellikine, Inc., a biopharmaceutical company, from 2007 to 2010. Dr. Velleca most recently served as Executive Vice President at The Leukemia & Lymphoma Society from April 2012 to April 2014. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Dr. Velleca received his B.S. from Yale University, and his M.D. and Ph.D. from Washington University in St. Louis.
Rajesh K. Malik

RajeshK.Malik,医学博士,自2014年7月起担任我们的首席医疗官。他在制药和生物技术行业和学术医学的药物开发的所有阶段拥有超过20年的经验,专注于肿瘤学。在成为我们的首席医疗官之前,Malik博士从2013年5月到2014年7月担任业务,临床和监管事务的顾问,包括从2013年7月到2014年6月担任我们公司的顾问。在加入我们之前,Malik博士于2007年1月至2013年9月担任德国生物技术公司Agennix AG的首席医疗官,并于2009年11月至2013年9月担任Agennix AG的管理委员会成员。从2004年9月到2007年1月,Malik博士还担任Adherex Technologies,Inc.的首席医疗官,这是一家生物制药公司。Malik博士还担任弗吉尼亚大学医学中心(University of Virginia Medical Center)和弗吉尼亚大学医学院(University of Virginia School of Medicine)的主治医师。Malik博士获得工商管理硕士学位和工商管理硕士学位。来自University of Sheffield Medical School。


Rajesh K. Malik, M.D., has served as our Chief Medical Officer since July 2014. He has over 20 years of experience in all phases of drug development in the pharmaceutical and biotechnology industry and academic medicine, with a focus in oncology. Prior to becoming our Chief Medical Officer, Dr. Malik served as a consultant for business, clinical and regulatory matters from May 2013 through July 2014 including as a consultant to our Company from July 2013 to June 2014. Prior to joining us, Dr. Malik served as Chief Medical Officer of Agennix AG, a German biotechnology company, from January 2007 to September 2013 and as a member of the management board of Agennix AG from November 2009 to September 2013. Dr. Malik also served as Chief Medical Officer of Adherex Technologies, Inc., a biopharmaceutical company, from September 2004 to January 2007. Dr. Malik also served as an attending physician at University of Virginia Medical Center and on the faculty of the University of Virginia School of Medicine. Dr. Malik received his M.B. and Ch.B. from the University of Sheffield Medical School.
RajeshK.Malik,医学博士,自2014年7月起担任我们的首席医疗官。他在制药和生物技术行业和学术医学的药物开发的所有阶段拥有超过20年的经验,专注于肿瘤学。在成为我们的首席医疗官之前,Malik博士从2013年5月到2014年7月担任业务,临床和监管事务的顾问,包括从2013年7月到2014年6月担任我们公司的顾问。在加入我们之前,Malik博士于2007年1月至2013年9月担任德国生物技术公司Agennix AG的首席医疗官,并于2009年11月至2013年9月担任Agennix AG的管理委员会成员。从2004年9月到2007年1月,Malik博士还担任Adherex Technologies,Inc.的首席医疗官,这是一家生物制药公司。Malik博士还担任弗吉尼亚大学医学中心(University of Virginia Medical Center)和弗吉尼亚大学医学院(University of Virginia School of Medicine)的主治医师。Malik博士获得工商管理硕士学位和工商管理硕士学位。来自University of Sheffield Medical School。
Rajesh K. Malik, M.D., has served as our Chief Medical Officer since July 2014. He has over 20 years of experience in all phases of drug development in the pharmaceutical and biotechnology industry and academic medicine, with a focus in oncology. Prior to becoming our Chief Medical Officer, Dr. Malik served as a consultant for business, clinical and regulatory matters from May 2013 through July 2014 including as a consultant to our Company from July 2013 to June 2014. Prior to joining us, Dr. Malik served as Chief Medical Officer of Agennix AG, a German biotechnology company, from January 2007 to September 2013 and as a member of the management board of Agennix AG from November 2009 to September 2013. Dr. Malik also served as Chief Medical Officer of Adherex Technologies, Inc., a biopharmaceutical company, from September 2004 to January 2007. Dr. Malik also served as an attending physician at University of Virginia Medical Center and on the faculty of the University of Virginia School of Medicine. Dr. Malik received his M.B. and Ch.B. from the University of Sheffield Medical School.
Gregory J. Mossinghoff

GregoryJ.Mossinghoff自2015年2月起担任我们的首席商务官兼秘书,并于2014年6月至2015年1月为我们提供财务管理,战略规划和业务发展咨询服务。他在战略规划、技术估值、合伙、资本市场和筹资方面有着20多年的经验。Mossinghoff先生于2010年8月至2015年1月担任Zoion Pharma,Inc.的执行Vice President兼首席商务官,并自2010年8月起担任Zoion Pharma,Inc.的董事会成员。Zoion Pharma,Inc.开发用于犬角结膜炎等兽医疾病的药物。Mossinghoff从2005年到2014年担任生物制药行业顾问,从2010年到2013年12月担任Novolipid,Inc.(一家肿瘤药物发现公司)联合创始人、总裁和首席执行官;2006年至2010年,内分泌受体肿瘤药物发现和开发公司Integrated Oncology Solutions,Inc.的总裁兼首席执行官和董事会成员;以及InspirePharmaceuticals,Inc.的总裁兼首席商务官和董事会成员,一家公开上市的生物制药公司,从1998年到2005年,随后于2011年被默克制药公司收购。Mossinghoff先生在弗吉尼亚大学(University of Virginia)获得学士学位,在乔治梅森大学(George Mason University)获得工商管理硕士学位。


Gregory J. Mossinghoff has served as our Chief Business Officer and Secretary since February 2015 and provided financial management, strategic planning and business development consulting services to our Company from June 2014 through January 2015. He has more than 20 years of experience in strategic planning, technology valuation, partnering, capital markets and fundraising. Mr. Mossinghoff served as Executive Vice President, Chief Business Officer of Zoion Pharma, Inc. from August 2010 to January 2015 and as a member of the board of directors of Zoion Pharma, Inc., since August 2010. Zoion Pharma, Inc. develops drugs for veterinary disorders such as canine keratoconjunctivitis. In addition to his work as a consultant in the biopharmaceutical industry from 2005 to 2014 Mr. Mossinghoff served as Co-Founder, President and Chief Executive Officer of NovoLipid, Inc., an oncology drug discovery company, from 2010 to December 2013; Co-Founder, President and Chief Executive Officer and a member of the board of directors of Integrated Oncology Solutions, Inc., an endocrine receptor oncology drug discovery and development company, from 2006 to 2010; and President, Chief Business Officer and a member of the board of directors of Inspire Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 1998 to 2005 which was subsequently acquired by Merck & Co., Inc. in 2011. Mr. Mossinghoff received his B.A. from the University of Virginia and his M.B.A. from George Mason University.
GregoryJ.Mossinghoff自2015年2月起担任我们的首席商务官兼秘书,并于2014年6月至2015年1月为我们提供财务管理,战略规划和业务发展咨询服务。他在战略规划、技术估值、合伙、资本市场和筹资方面有着20多年的经验。Mossinghoff先生于2010年8月至2015年1月担任Zoion Pharma,Inc.的执行Vice President兼首席商务官,并自2010年8月起担任Zoion Pharma,Inc.的董事会成员。Zoion Pharma,Inc.开发用于犬角结膜炎等兽医疾病的药物。Mossinghoff从2005年到2014年担任生物制药行业顾问,从2010年到2013年12月担任Novolipid,Inc.(一家肿瘤药物发现公司)联合创始人、总裁和首席执行官;2006年至2010年,内分泌受体肿瘤药物发现和开发公司Integrated Oncology Solutions,Inc.的总裁兼首席执行官和董事会成员;以及InspirePharmaceuticals,Inc.的总裁兼首席商务官和董事会成员,一家公开上市的生物制药公司,从1998年到2005年,随后于2011年被默克制药公司收购。Mossinghoff先生在弗吉尼亚大学(University of Virginia)获得学士学位,在乔治梅森大学(George Mason University)获得工商管理硕士学位。
Gregory J. Mossinghoff has served as our Chief Business Officer and Secretary since February 2015 and provided financial management, strategic planning and business development consulting services to our Company from June 2014 through January 2015. He has more than 20 years of experience in strategic planning, technology valuation, partnering, capital markets and fundraising. Mr. Mossinghoff served as Executive Vice President, Chief Business Officer of Zoion Pharma, Inc. from August 2010 to January 2015 and as a member of the board of directors of Zoion Pharma, Inc., since August 2010. Zoion Pharma, Inc. develops drugs for veterinary disorders such as canine keratoconjunctivitis. In addition to his work as a consultant in the biopharmaceutical industry from 2005 to 2014 Mr. Mossinghoff served as Co-Founder, President and Chief Executive Officer of NovoLipid, Inc., an oncology drug discovery company, from 2010 to December 2013; Co-Founder, President and Chief Executive Officer and a member of the board of directors of Integrated Oncology Solutions, Inc., an endocrine receptor oncology drug discovery and development company, from 2006 to 2010; and President, Chief Business Officer and a member of the board of directors of Inspire Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 1998 to 2005 which was subsequently acquired by Merck & Co., Inc. in 2011. Mr. Mossinghoff received his B.A. from the University of Virginia and his M.B.A. from George Mason University.
Jay Strum

Jay Strum博士自2009年以来一直担任我们的首席科学官,此外还从2011年至2014年担任我们的总裁兼董事会成员。在加入我们之前,Strum博士从1995年5月到2009年2月担任英国制药公司GlaxoSmithKline plc(GSK)基因组学部门的科学家、经理和董事,在那里他开发了多个治疗领域和目标类别的药物,重点是激酶。在GSK担任经理期间,Strum博士担任代谢性疾病和肿瘤学早期药物发现跨学科研究与开发团队的项目负责人,并为众多候选药物的发现和包括Tykerb在内的三种批准药物的开发做出了贡献。作为GSK基因组学部门的总监,他领导了一个国际部门的创建和运营,负责支持GSK内部所有治疗领域的基因组学研究。Strum博士是40多个科学出版物的作者,也是涵盖Trilaciclib或G1T38或其使用方法的公司拥有或共同拥有的所有知识产权的共同发明人,该公司由11个专利家族组成,拥有5个已发行的美国专利。Strum博士还是另外六个专利家族和六个已发布专利的共同发明人,这些专利涵盖了其他感兴趣的化合物。总的来说,Strum博士是超过75个应用程序的共同发明人,这些应用程序已经在美国以外的国家进入了国家起诉阶段。Strum博士在西卡罗莱纳大学(Western Carolina University)获得学士学位和学士学位,并在维克森林大学(Wake Forest University)获得生物化学博士学位。


Jay Strum, Ph.D., has served as our Chief Scientific Officer since 2009 and in addition to this role, served as our President and a member of our board of directors from 2011 until 2014. Prior to joining us, Dr. Strum served as a scientist, manager and then Director of the Genomics Division at GlaxoSmithKline plc, or GSK, a British pharmaceutical company, from May 1995 to February 2009 where he developed drugs in multiple therapeutic areas and target classes with a focus on kinases. In his role as a manager at GSK, Dr. Strum served as a program leader of interdisciplinary research and development teams in early drug discovery in metabolic diseases and oncology, and he contributed to the discovery of numerous drug candidates and the development of three approved drugs, including TYKERB. As the Director of the Genomics Division at GSK, he led the creation and operation of an international department responsible for supporting genomics research in all therapeutic areas within GSK. Dr. Strum is the author of more than 40 scientific publications and co-inventor of all intellectual property owned or co-owned by the Company that covers trilaciclib or G1T38 or their method of use, which consists of 11 patent families with five issued U.S. patents. Dr. Strum is also the co-inventor of another six patent families and six issued patents that cover additional compounds of interest. In total, Dr. Strum is a co-inventor of more than 75 applications that have entered the national phase of prosecution in countries outside the United States. Dr. Strum received his B.S. and B.A. from Western Carolina University and his Ph.D. in biochemistry from Wake Forest University.
Jay Strum博士自2009年以来一直担任我们的首席科学官,此外还从2011年至2014年担任我们的总裁兼董事会成员。在加入我们之前,Strum博士从1995年5月到2009年2月担任英国制药公司GlaxoSmithKline plc(GSK)基因组学部门的科学家、经理和董事,在那里他开发了多个治疗领域和目标类别的药物,重点是激酶。在GSK担任经理期间,Strum博士担任代谢性疾病和肿瘤学早期药物发现跨学科研究与开发团队的项目负责人,并为众多候选药物的发现和包括Tykerb在内的三种批准药物的开发做出了贡献。作为GSK基因组学部门的总监,他领导了一个国际部门的创建和运营,负责支持GSK内部所有治疗领域的基因组学研究。Strum博士是40多个科学出版物的作者,也是涵盖Trilaciclib或G1T38或其使用方法的公司拥有或共同拥有的所有知识产权的共同发明人,该公司由11个专利家族组成,拥有5个已发行的美国专利。Strum博士还是另外六个专利家族和六个已发布专利的共同发明人,这些专利涵盖了其他感兴趣的化合物。总的来说,Strum博士是超过75个应用程序的共同发明人,这些应用程序已经在美国以外的国家进入了国家起诉阶段。Strum博士在西卡罗莱纳大学(Western Carolina University)获得学士学位和学士学位,并在维克森林大学(Wake Forest University)获得生物化学博士学位。
Jay Strum, Ph.D., has served as our Chief Scientific Officer since 2009 and in addition to this role, served as our President and a member of our board of directors from 2011 until 2014. Prior to joining us, Dr. Strum served as a scientist, manager and then Director of the Genomics Division at GlaxoSmithKline plc, or GSK, a British pharmaceutical company, from May 1995 to February 2009 where he developed drugs in multiple therapeutic areas and target classes with a focus on kinases. In his role as a manager at GSK, Dr. Strum served as a program leader of interdisciplinary research and development teams in early drug discovery in metabolic diseases and oncology, and he contributed to the discovery of numerous drug candidates and the development of three approved drugs, including TYKERB. As the Director of the Genomics Division at GSK, he led the creation and operation of an international department responsible for supporting genomics research in all therapeutic areas within GSK. Dr. Strum is the author of more than 40 scientific publications and co-inventor of all intellectual property owned or co-owned by the Company that covers trilaciclib or G1T38 or their method of use, which consists of 11 patent families with five issued U.S. patents. Dr. Strum is also the co-inventor of another six patent families and six issued patents that cover additional compounds of interest. In total, Dr. Strum is a co-inventor of more than 75 applications that have entered the national phase of prosecution in countries outside the United States. Dr. Strum received his B.S. and B.A. from Western Carolina University and his Ph.D. in biochemistry from Wake Forest University.
Jennifer K. Moses

JenniferK.Moses自2015年3月起担任我们的财务和行政Vice President,并于2012年10月至2015年2月为我们公司提供财务咨询服务。Moses从2007年10月到2015年2月担任RankinMcKenzie,LLC(一家专业金融和会计服务公司)合伙人,为私人公司提供金融服务。此前,她曾担任Deloitte LLP的税务服务集团的高级经理,在那里她曾服务从小型新兴成长型公司到大型上市公司的客户。Moses女士在宾夕法尼亚州立大学(Pennsylvania State University)获得学士学位,是一名注册会计师。


Jennifer K. Moses has served as our Vice President of Finance and Administration since March 2015 and provided financial consulting services to our Company from October 2012 through February 2015. From October 2007 through February 2015 Ms. Moses was a partner of RankinMcKenzie, LLC, a professional finance and accounting services firm, and provided financial services to private companies. Previously, she was a senior manager in the tax services group at Deloitte LLP, where she served clients ranging from small, emerging growth companies to large, publicly traded companies. Ms. Moses received her B.S. from Pennsylvania State University and is a certified public accountant.
JenniferK.Moses自2015年3月起担任我们的财务和行政Vice President,并于2012年10月至2015年2月为我们公司提供财务咨询服务。Moses从2007年10月到2015年2月担任RankinMcKenzie,LLC(一家专业金融和会计服务公司)合伙人,为私人公司提供金融服务。此前,她曾担任Deloitte LLP的税务服务集团的高级经理,在那里她曾服务从小型新兴成长型公司到大型上市公司的客户。Moses女士在宾夕法尼亚州立大学(Pennsylvania State University)获得学士学位,是一名注册会计师。
Jennifer K. Moses has served as our Vice President of Finance and Administration since March 2015 and provided financial consulting services to our Company from October 2012 through February 2015. From October 2007 through February 2015 Ms. Moses was a partner of RankinMcKenzie, LLC, a professional finance and accounting services firm, and provided financial services to private companies. Previously, she was a senior manager in the tax services group at Deloitte LLP, where she served clients ranging from small, emerging growth companies to large, publicly traded companies. Ms. Moses received her B.S. from Pennsylvania State University and is a certified public accountant.